- call +1-201-465-4211
- email sales@mrinsights.biz
Lung cancer or lung carcinoma is a disease characterized by uncontrolled cell growth in the lungs. Common symptoms include cough, chest pain, weight loss, and shortness of breath. Due an increase in the incidence of lung cancer, the global lung cancer therapeutics market is expected to expand at a rapid pace.
Scope of the Report:
This report studies the Non-Small Cell Lung Cancer Therapeutics market status and outlook of Global and major regions, from angles of players, countries, product types and end industries; this report analyzes the top players in global market, and splits the Non-Small Cell Lung Cancer Therapeutics market by product type and applications/end industries.
Non-small cell lung cancer is the most common type of lung cancer that causes mortality and morbidity in both developed and developing countries. The approval of late-stage pipeline products like onartuzumab and necitumumab is expected to foster growth in this market, resulting in its steady market growth.
The global Non-Small Cell Lung Cancer Therapeutics market is valued at xx million USD in 2017 and is expected to reach xx million USD by the end of 2023, growing at a CAGR of xx% between 2017 and 2023.
The Asia-Pacific will occupy for more market share in following years, especially in China, also fast growing India and Southeast Asia regions.
North America, especially The United States, will still play an important role which cannot be ignored. Any changes from United States might affect the development trend of Non-Small Cell Lung Cancer Therapeutics.
Europe also play important roles in global market, with market size of xx million USD in 2017 and will be xx million USD in 2023, with a CAGR of xx%.
Market Segment by Companies, this report covers
GlaxoSmithKline
Novartis
AstraZeneca
Roche
Bristol-Myers Squibb
Pfizer
Eli Lilly
Sanofi
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Biologics
Small molecules
Market Segment by Applications, can be divided into
Hospital
Clinic
The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.
Market is segmented on the basis:
The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.
The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.
Table of Contents
1 Non-Small Cell Lung Cancer Therapeutics Market Overview
1.1 Product Overview and Scope of Non-Small Cell Lung Cancer Therapeutics
1.2 Classification of Non-Small Cell Lung Cancer Therapeutics by Types
1.2.1 Global Non-Small Cell Lung Cancer Therapeutics Revenue Comparison by Types (2017-2023)
1.2.2 Global Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Types in 2017
1.2.3 Biologics
1.2.4 Small molecules
1.3 Global Non-Small Cell Lung Cancer Therapeutics Market by Application
1.3.1 Global Non-Small Cell Lung Cancer Therapeutics Market Size and Market Share Comparison by Applications (2013-2023)
1.3.2 Hospital
1.3.3 Clinic
1.4 Global Non-Small Cell Lung Cancer Therapeutics Market by Regions
1.4.1 Global Non-Small Cell Lung Cancer Therapeutics Market Size (Million USD) Comparison by Regions (2013-2023)
1.4.1 North America (USA, Canada and Mexico) Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
1.4.2 Europe (Germany, France, UK, Russia and Italy) Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia) Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
1.4.4 South America (Brazil, Argentina, Colombia) Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
1.4.5 Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa) Non-Small Cell Lung Cancer Therapeutics Status and Prospect (2013-2023)
1.5 Global Market Size of Non-Small Cell Lung Cancer Therapeutics (2013-2023)
2 Manufacturers Profiles
2.1 GlaxoSmithKline
2.1.1 Business Overview
2.1.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.1.2.1 Product A
2.1.2.2 Product B
2.1.3 GlaxoSmithKline Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.2 Novartis
2.2.1 Business Overview
2.2.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.2.2.1 Product A
2.2.2.2 Product B
2.2.3 Novartis Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.3 AstraZeneca
2.3.1 Business Overview
2.3.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.3.2.1 Product A
2.3.2.2 Product B
2.3.3 AstraZeneca Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.4 Roche
2.4.1 Business Overview
2.4.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.4.2.1 Product A
2.4.2.2 Product B
2.4.3 Roche Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.5 Bristol-Myers Squibb
2.5.1 Business Overview
2.5.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.5.2.1 Product A
2.5.2.2 Product B
2.5.3 Bristol-Myers Squibb Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.6 Pfizer
2.6.1 Business Overview
2.6.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.6.2.1 Product A
2.6.2.2 Product B
2.6.3 Pfizer Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.7 Eli Lilly
2.7.1 Business Overview
2.7.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.7.2.1 Product A
2.7.2.2 Product B
2.7.3 Eli Lilly Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
2.8 Sanofi
2.8.1 Business Overview
2.8.2 Non-Small Cell Lung Cancer Therapeutics Type and Applications
2.8.2.1 Product A
2.8.2.2 Product B
2.8.3 Sanofi Non-Small Cell Lung Cancer Therapeutics Revenue, Gross Margin and Market Share (2016-2017)
3 Global Non-Small Cell Lung Cancer Therapeutics Market Competition, by Players
3.1 Global Non-Small Cell Lung Cancer Therapeutics Revenue and Share by Players (2013-2018)
3.2 Market Concentration Rate
3.2.1 Top 5 Non-Small Cell Lung Cancer Therapeutics Players Market Share
3.2.2 Top 10 Non-Small Cell Lung Cancer Therapeutics Players Market Share
3.3 Market Competition Trend
4 Global Non-Small Cell Lung Cancer Therapeutics Market Size by Regions
4.1 Global Non-Small Cell Lung Cancer Therapeutics Revenue and Market Share by Regions
4.2 North America Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
4.3 Europe Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
4.4 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
4.5 South America Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
4.6 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
5 North America Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
5.1 North America Non-Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
5.2 USA Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
5.3 Canada Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
5.4 Mexico Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
6 Europe Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
6.1 Europe Non-Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
6.2 Germany Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
6.3 UK Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
6.4 France Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
6.5 Russia Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
6.6 Italy Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
7 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
7.1 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
7.2 China Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
7.3 Japan Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
7.4 Korea Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
7.5 India Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
7.6 Southeast Asia Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
8 South America Non-Small Cell Lung Cancer Therapeutics Revenue by Countries
8.1 South America Non-Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
8.2 Brazil Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
8.3 Argentina Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
8.4 Colombia Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
9 Middle East and Africa Revenue Non-Small Cell Lung Cancer Therapeutics by Countries
9.1 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Revenue by Countries (2013-2018)
9.2 Saudi Arabia Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
9.3 UAE Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
9.4 Egypt Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
9.5 Nigeria Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
9.6 South Africa Non-Small Cell Lung Cancer Therapeutics Revenue and Growth Rate (2013-2018)
10 Global Non-Small Cell Lung Cancer Therapeutics Market Segment by Type
10.1 Global Non-Small Cell Lung Cancer Therapeutics Revenue and Market Share by Type (2013-2018)
10.2 Global Non-Small Cell Lung Cancer Therapeutics Market Forecast by Type (2018-2023)
10.3 Biologics Revenue Growth Rate (2013-2023)
10.4 Small molecules Revenue Growth Rate (2013-2023)
11 Global Non-Small Cell Lung Cancer Therapeutics Market Segment by Application
11.1 Global Non-Small Cell Lung Cancer Therapeutics Revenue Market Share by Application (2013-2018)
11.2 Non-Small Cell Lung Cancer Therapeutics Market Forecast by Application (2018-2023)
11.3 Hospital Revenue Growth (2013-2018)
11.4 Clinic Revenue Growth (2013-2018)
12 Global Non-Small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)
12.1 Global Non-Small Cell Lung Cancer Therapeutics Market Size Forecast (2018-2023)
12.2 Global Non-Small Cell Lung Cancer Therapeutics Market Forecast by Regions (2018-2023)
12.3 North America Non-Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
12.4 Europe Non-Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
12.5 Asia-Pacific Non-Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
12.6 South America Non-Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
12.7 Middle East and Africa Non-Small Cell Lung Cancer Therapeutics Revenue Market Forecast (2018-2023)
13 Research Findings and Conclusion
14 Appendix
14.1 Methodology
14.2 Data Source
List of Tables and Figures
Figure Non-Small Cell Lung Cancer Therapeutics Picture
Table Product Specifications of Non-Small Cell Lung Cancer Therapeutics
Table Global Non-Small Cell Lung Cancer Thera
ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems
Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system
Global Outreach6 Major regions and 40+ countries level analysis accomplished
Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery
